Cleared Traditional

K991413 - CODMAN ETHISORB DURA PATCH

K991413 is the FDA 510(k) clearance for CODMAN ETHISORB DURA PATCH by Johnson & Johnson Professionals, Inc.. It is a Class 2 Neurology device (product code GXQ) cleared through the Traditional 510(k) pathway after a 325-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 2000
Decision
325d
Days
Class 2
Risk

K991413 is an FDA 510(k) clearance for the CODMAN ETHISORB DURA PATCH. Classified as Dura Substitute (product code GXQ), Class II - Special Controls.

Submitted by Johnson & Johnson Professionals, Inc. (Raynham, US). The FDA issued a Cleared decision on March 13, 2000 after a review of 325 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5910 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.

View all Johnson & Johnson Professionals, Inc. devices

Submission Details

510(k) Number K991413 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 23, 1999
Decision Date March 13, 2000
Days to Decision 325 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
177d slower than avg
Panel avg: 148d · This submission: 325d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GXQ Dura Substitute
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5910
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Peers - GXQ Dura Substitute

All 29
Devices cleared under the same product code (GXQ) and FDA review panel - the closest regulatory comparables to K991413.
DURAGEN PLUS DURAL GRAFT MATRIX
K032693 · Integra Lifesciences Corp. · Sep 2003
DURASIS DURAL SUBSTITUTE
K031850 · Cook Biotech, Inc. · Sep 2003
PRECLUDE MVP DURA SUBSTITUTE
K021477 · W.L. Gore & Associates, Inc. · Nov 2002
DURAGEN DURAL GRAFT MATRIX
K982180 · Integra Lifesciences Corp. · Jul 1999
PRECLUDE ACUSEAL DURA SUBSTITUTE
K984534 · W.L. Gore & Associates, Inc. · Mar 1999
LYOPLANT DURA SUBSTITUTE(VARIOUS)
K970851 · Aesculap, Inc. · Dec 1997